Equities

Oncopeptides AB

Oncopeptides AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)2.17
  • Today's Change0.035 / 1.64%
  • Shares traded607.54k
  • 1 Year change-62.11%
  • Beta-0.4630
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments173345362
Total Receivables, Net181738
Total Inventory2.4300
Prepaid expenses9.162.2512
Other current assets, total----0.00
Total current assets203364412
Property, plant & equipment, net352025
Goodwill, net------
Intangibles, net001.41
Long term investments0.850.850.85
Note receivable - long term------
Other long term assets------
Total assets238385439
LIABILITIES
Accounts payable152836
Accrued expenses1619122
Notes payable/short-term debt000
Current portion long-term debt/capital leases5.136.0011
Other current liabilities, total9.083357
Total current liabilities4586225
Total long term debt1373.543.21
Total debt1429.5414
Deferred income tax------
Minority interest------
Other liabilities, total--1.820.01
Total liabilities18291229
SHAREHOLDERS EQUITY
Common stock11108.37
Additional paid-in capital5,4145,4034,982
Retained earnings (accumulated deficit)(5366)(5116)(4778)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(2.2)(2.3)(0.92)
Total equity57294211
Total liabilities & shareholders' equity238385439
Total common shares outstanding127127106
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.